Pharmacist-led Hepatitis C Management

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-13

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatitis C virus (HCV) continues to disproportionately affect vulnerable and marginalized persons in Canada. During the interferon treatment era, certain circumstances precluded individuals from receiving treatment, most notably mental health concerns or active substance use. In addition to the tolerability and efficacy of all-oral direct acting antivirals (DAAs), novel diagnostic strategies have also increased engagement in the care cascade. Point-of care and/or dried blood spot antibody as well as RNA testing allow for diagnosis without the need for phlebotomy, a major barrier for those with a history of past or current injection drug use. Despite these advances in diagnostic streamlining and increased cure rates, engagement post-diagnosis continues to be a major gap. Although the exact mechanism of HCV acquisition may not be clear - people who inject drugs, persons who are street-involved or low-income, or persons who are difficult-to-reach for other reasons, often experience both structural and geographic challenges to obtaining care. Community pharmacists may be the first point of contact for higher risk populations and may avoid testing and/or treatment for fear of judgement or poor treatment in hospital/specialist settings. While studies have demonstrated the feasibility of treating people receiving opioid against therapy (OAT), it remains unclear whether Canadian pharmacists can safely and effectively screen, and/or confirm HCV, work-up patients for HCV treatment, and prescribe with minimal oversight. If this model proves successful, it may have global utility especially in areas of the world where pharmacists are the initial point of contact for healthcare issues. The aim of this study is to determine whether being tested and linked care and treatment will be more effective in a community pharmacy than a referral to a tertiary care hospital for management of HCV among people on stable OAT, or other populations who experience barriers to care but use community pharmacy services.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HCV Treatment Initiation During Acute Psychiatric Admission

NCT04625322

Hepatitis C

UNKNOWN PHASE4

Re-link HCV in Substance-Use Telemedicine Program

NCT06349902

Hepatitis C

RECRUITING

Hepatitis C Pharmacy-based Strategy for Injectors

NCT04698629

Hepatitis C

COMPLETED

Testing and Treating Hepatitis C in Community Pharmacies

NCT02706223

Hepatitis C

COMPLETED NA

Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)

NCT01448915

HIV Infection Hepatitis C

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C Virus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Screening, evaluation and treatment at an outpatient pharmacy compared to referral to hepatology clinics

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Community Pharmacist-Led

Patients in Arm 1 will receive care and treatment at their home pharmacy and be evaluated and treated by a community pharmacist under medical directives and with study oversight.

Group Type EXPERIMENTAL

Pharmacist-Led care

Intervention Type BEHAVIORAL

Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led

Academic hepatology

Patients in Arm 2 will be evaluated and treated by hepatologists at the Toronto Centre for Liver Disease.

Group Type ACTIVE_COMPARATOR

Standard of Care (Hepatology)

Intervention Type BEHAVIORAL

Rapid testing in a community pharmacy, with standard of care referral to academic hepatology

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacist-Led care

Rapid testing in a community pharmacy, with rapid linkage to care and treatment that is pharmacist-led

Intervention Type BEHAVIORAL

Standard of Care (Hepatology)

Rapid testing in a community pharmacy, with standard of care referral to academic hepatology

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. HCV infection
2. HCV RNA \> 1,000 IU/mL
3. Aged 18 to 80
4. Willingness and capacity to provide informed consent

Exclusion Criteria

1. Presence of or history of decompensated cirrhosis. This will be defined as evidence of clinical decompensation (history of either ascites, variceal hemorrhage, or hepatic encephalopathy/confusion), and Child-Pugh-Turcotte and Model for Endstage Liver Disease (MELD) score will also be used to assess this using laboratory investigations and clinical findings.
2. Platelets \< 75,000/mm3, total albumin \<35 g/L, total bilirubin (total and direct) \>34.2 μmol/L, International Normalized Ratio (INR) \>1.5
3. History of current or past hepatocellular carcinoma
4. Hepatitis B virus (HBV) co-infection as indicated by positive testing for hepatitis B surface antigen (HBsAg +ve)or untreated HIV co-infection
5. Prior HCV antiviral therapy with direct-acting antivirals with or without peginterferon/ribavirin
6. Chronic liver disease other than mild non-alcoholic or alcoholic fatty liver disease from a cause other than HCV
7. Significant co-morbid illness that precludes inclusion in the opinion of the investigator
8. Life expectancy of less than 1 year. If clarity is required, the provider who delivered the diagnosis will be contacted.
9. Pregnancy/breast-feeding/inability to use contraception
10. Use of concomitant contraindicated drugs

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No